Expression levels of caspase-3 and gasdermin E and their involvement in the occurrence and prognosis of lung cancer

Yuan-Li Huang | Guang-Hui Zhang | Qing Zhu | Xia Wu | Li-Gao Wu

Department of Pathology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

Correspondence
Li-Gao Wu, Department of Pathology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province, China. Email: wlgahbb@126.com

Funding information
Graduate School of Bengbu Medical College, Grant/Award Number: Byycx20068

Abstract

Background: Pyroptosis plays a dual role in the development of cancer and malignancy; as such, it may potentially be a new target for cancer treatment. However, the inflammatory response to pyroptosis may have adverse effects on the body. The roles of gasdermin E (GSDME), caspases, and related proteins associated with pyroptosis in cancer remain controversial.

Aim: The goal of this study was to determine whether the expression levels of caspase-3 and GSDME affect the clinical stage, pathological grade, or survival prognosis of patients with lung cancer.

Methods: We examined the protein levels of GSDME, caspase-3, caspase-8, and caspase-9 in lung tissue samples from 100 patients with lung cancer by using immunohistochemistry.

Results: We found that GSDME, caspase-3, and caspase-8 were more highly expressed in tumor tissues than in adjacent normal tissues. Moreover, we found that GSDME could serve as a prognostic factor as there was a positive correlation between its expression level and the postoperative survival rate of patients with lung cancer.

Conclusions: GSDME may be an independent factor affecting the prognosis of patients with lung cancer. However, the role of GSDME and its related proteins in cancer requires further research.

KEYWORDS
caspase-8, immunohistochemistry, inflammatory, pyroptosis, survival rate

1 | BACKGROUND

Over the past decade, there have been significant advancements in research on the epidemiology and prevention of lung cancer through our understanding of the underlying genetics and of the role of the immune system in lung cancer control, and breakthroughs in treatment options. Despite these advances, lung cancer remains the leading cause of cancer-related deaths. This may be attributable to detection at later stages, as lung cancer is initially asymptomatic. Furthermore, the high mortality rate may be due to limited treatment strategies for patients with advanced-stage lung cancer.

Worldwide, lung cancer cases and deaths are on the rise; in 2018, GLOBOCAN estimated 2.09 million new cases (11.6% of total cancer cases) and 1.76 million deaths (18.4% of total cancer deaths), as opposed to 1.8 million new cases and 1.6 million deaths from lung cancer reported in 2012. It the most common cancer as well as the leading cause of cancer-related death in both men and women. In women alone, it is the third most common cancer type and the second leading cause of cancer-related death
Furthermore, lung cancer rates in developing countries are expected to continue to rise over time.

Pyroptosis is a newly discovered programmed cell death mode that has features of both apoptosis and necrosis. Pyroptosis is a pro-inflammatory cell death form dependent on the caspase family, and is a programmed cell death pattern. The role of cell pyroptosis in the development of cancer has attracted a large amount of attention. However, our understanding of pyroptosis is still scanty, and the molecular mechanisms behind pyroptosis and its incidence need to be further explored. At present, pyroptosis is thought to occur via a classical pathway and a non-classical pathway mediated by an “executive protein” known as gasdermin D (GSDMD). This protein relies on two caspase-mediated pathways, namely, the caspase-1 and caspase-4/5/11 pathways.

GSDMD and gasdermin E (GSDME) belong to the gasdermin family of proteins, which share pore-forming domains. Unlike GSDMD, the cleavage of GSDME does not involve the caspase-1 or caspase-4/5/11 pathways; instead, it relies on another member of the caspase family, caspase-3. The known caspase-3-mediated cell death mode is apoptosis, but when GSDME is present, its expression level, if high, modulates this to lead to pyroptosis instead. In addition, the mechanisms of cell membrane pore formation by other members of the gasdermin family, such as GSDMA, GSDMB, and GSDMC, remain unclear.

In this study, we explored the role of GSDME and demonstrated that under the mediation of caspase-3, it splits into the GSDME C-terminal and the GSDME N-terminal. The GSDME-N terminals then accumulate on the cell membrane, leading to the formation of transmembrane pores. This effectively destroys the integrity of the cell membrane, leading to cell disintegration, cell death, and secondary inflammatory reactions. It is noteworthy that caspase-3 cleaves GSDME but not GSDMD. The expression of GSDME is inhibited in most cancer tissues and as such, GSDME may act a tumor suppressor. Moreover, in breast cancer, a decrease in the levels of GSDME is associated with a decrease in survival rate.

### MATERIALS AND METHODS

#### 2.1 General information

From January 2013 to December 2014, a total of 100 archived paraffin-embedded lung cancer specimens confirmed by the Department of Pathology of The First Affiliated Hospital of the Bengbu Medical College were collected. None of the patients with lung cancer received radiotherapy or chemotherapy before surgery. The age range of the patients was 45–81 years, with a median age of 65. All cases were followed up until the death of the patient or until January 2020, with the shortest interval at 60 months and the longest interval at 84 months. This research has been approved by the Ethics Committee of (Blinded per Author Guidelines), and follows the ethical guidelines of the Helsinki Declaration.

All the patients enrolled in this study underwent radical lung cancer surgery, and their specimens were confirmed by the Department of Pathology of The First Affiliated Hospital of the Bengbu Medical College were collected. The baseline data of the selected cases were collected retrospectively; follow up was by telephone. The clinicopathological data of the patients are shown in Table 1.

| Characteristics | No of cases (%) |
|-----------------|----------------|
| **Age**         |                |
| >65             | 79 (71.8)      |
| ≤65             | 21 (19.1)      |
| **Gender**      |                |
| Male            | 51 (46.4)      |
| Female          | 49 (44.5)      |
| **Pathological grade** |          |
| I               | 25 (22.7)      |
| II              | 51 (46.4)      |
| III             | 24 (21.8)      |
| **TNM stage**   |                |
| I               | 29 (26.4)      |
| II              | 31 (28.2)      |
| III             | 40 (36.4)      |
| **Lymphatic invasion** |         |
| Yes             | 43 (39.1)      |
| No              | 57 (51.8)      |
| **Vital states**|                |
| Alive           | 38 (34.5)      |
| Dead            | 62 (56.4)      |
| **Expression of gasdermin E** |        |
| Low expression  | 52 (47.3)      |
| High expression | 48 (43.6)      |
| **Expression of caspase-3** |       |
| Low expression  | 12 (10.9)      |
| High expression | 88 (80.0)      |
| **Expression of caspase-8** |         |
| Low expression  | 26 (23.6)      |
| High expression | 74 (67.3)      |
| **Expression of caspase-9** |       |
| Low expression  | 88 (80.0)      |
| High expression | 12 (10.9)      |
| **Tumor size**  |                |
| ≤5              | 74 (67.3)      |
| >5              | 26 (23.6)      |
| **Tumor location** |            |
| Central type    | 64 (58.2)      |
| Peripheral type | 36 (32.7)      |
| **Tumor types** |                |
| Squamous cell carcinoma | 67 (60.9) |
| Adenocarcinoma  | 31 (28.2)      |
| Small cell carcinoma | 2 (1.8)   |
2.2 | Reagents

Rabbit polyclonal antibodies against human caspase-3, caspase-8, caspase-9, and GSDME were purchased from Proteintech (Rosemont, IL, USA). The specific information about the antibodies is shown in Table 2. The ElivisionTM Plus Kit and DAB color developing kit were purchased from Fuzhou Maixin Biological Company (China).

2.3 | Experimental method

All lung cancer tissue samples were fixed in 10% neutral formalin solution. They were routinely collected, paraffin-embedded, and sectioned at 4 μm thickness. After hematoxylin/eosin and immunohistochemical staining, histological observations were conducted under a light microscope (Olympus light microscope). Clinical staging was performed according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (eighth Edition). Immunohistochemical staining using the ElivisionTM Plus Kit was performed according to the manufacturer’s instructions.

2.4 | Evaluation of immunoreactivity

The criteria for scoring GSDME were as follows. The intensity was graded according to the following scale: 0, negative; 1, weak; 2, moderate; and 3, strong. The proportion of the positive tumor cells was graded as follows: 0, <5%; 1, 5%–25%; 2, 26%–50%; 3, 51%–75%; 4, >75%. The final score was computed by multiplying these two primary scores. Final scores of 0–6 were defined as “low expression” or (−); final scores of 6–12 were defined as “high expression” or (+). The same method was used to evaluate the staining signals for caspase family proteins. The immunohistochemical staining results were determined by two pathologists using an independent double-blind method.

2.5 | Statistical analysis

SPSS 25.0 (IBM, Chicago, IL, USA) was used for statistical analysis. The Kaplan–Meier method was used for the survival analysis of caspase-3, caspase-8, caspase-9, and GSDME protein expression groups to draw univariate survival curves. The log-rank test was used for comparisons between groups, and the Cox multivariate regression model was used for the multi-factor analysis. In lung cancer tissues, the correlation between the expression levels of caspase-3, caspase-8, caspase-9, and GSDME as well as the clinicopathological parameters were analyzed by the χ² and Spearman rank correlation tests. Effects were considered statistically significant if p < .05.

| Antibody | Catalog Number | Source | Company | Dilution |
|----------|----------------|--------|---------|----------|
| Caspase-3 | 19 677-1-AP   | Rabbit polyclonal | Proteintech, Rosemont, IL, USA | 1:400 |
| Caspase-8 | 13 423-1-AP   | Rabbit polyclonal | Proteintech, Rosemont, IL, USA | 1:400 |
| Caspase-9 | 10 380-1-AP   | Rabbit polyclonal | Proteintech, Rosemont, IL, USA | 1:200 |
| GSDME    | 13 075-1-AP   | Rabbit polyclonal | Proteintech, Rosemont, IL, USA | 1:400 |

FIGURE 1 Expression of gasdermin E (GSDME), caspase-3, caspase-8, and caspase-9 in lung cancer. (A) High expression of GSDME in lung cancer tissue. Positive GSDME signal was present in the cytoplasm and cell membrane of cancer cells, which further suggested that GSDME accumulated in the cell membrane, leading to cell membrane pore formation and subsequent disintegration and necrosis. (B) Low expression of GSDME in lung cancer tissue. (C) High expression of caspase-3 in lung cancer tissue. (D) Low expression of caspase-3 in lung cancer tissue. (E) High expression of caspase-3 in lung cancer tissue. (F) Low expression of caspase-8 in lung cancer tissue. (G) High expression of caspase-8 in lung cancer tissue. (H) Low expression of caspase-9 in lung cancer tissue. (I) Low expression of caspase-9 in lung cancer tissue. (J) High expression of caspase-9 in lung cancer tissue. (K) Low expression of caspase-9 in lung cancer tissue. (L) High expression of caspase-9 in lung cancer tissue. (Images were acquired at 400× magnification)
| Variable               | GSDME Low | GSDME High | p value | caspase-3 Low | caspase-3 High | p value | caspase-8 Low | caspase-8 High | p value | caspase-9 Low | caspase-9 High | p value |
|------------------------|-----------|------------|---------|---------------|---------------|---------|---------------|---------------|---------|---------------|---------------|---------|
| Age                    |           |            |         |               |               |         |               |               |         |               |               |         |
| >65                    | 43        | 36         | 0.183   | 8             | 71            | 0.263   | 22            | 57            | 0.414   | 69            | 10            | 0.694   |
| <=65                   | 8         | 13         |          |               |               |         |               |               |         |               |               |         |
| Gender                 |           |            |         |               |               |         |               |               |         |               |               |         |
| Male                   | 27        | 24         | 0.692   | 7             | 44            | 0.588   | 16            | 35            | 0.211   | 44            | 7             | 0.588   |
| Female                 | 24        | 25         |          | 5             | 44            |          | 10            | 39            |         | 44            | 5             |         |
| Pathologic grade       |           |            |         |               |               |         |               |               |         |               |               |         |
| I                      | 10        | 15         | 0.135   | 2             | 23            | 0.303   | 6             | 19            | 0.329   | 24            | 1             | 0.341   |
| II                     | 31        | 20         |          | 5             | 46            |          | 11            | 40            |         | 44            | 7             |         |
| III                    | 10        | 14         |          | 5             | 19            |          | 9             | 15            |         | 20            | 4             |         |
| TNM stage              |           |            |         |               |               |         |               |               |         |               |               |         |
| I                      | 11        | 18         | 0.194   | 4             | 25            | 0.88    | 7             | 22            | 0.895   | 24            | 5             | 0.462   |
| II                     | 16        | 15         |          | 3             | 28            |          | 9             | 22            |         | 27            | 4             |         |
| III                    | 24        | 16         |          | 5             | 35            |          | 10            | 30            |         | 37            | 3             |         |
| Lymphatic invasion     |           |            |         |               |               |         |               |               |         |               |               |         |
| Yes                    | 28        | 15         | .014*   | 4             | 39            | 0.471   | 11            | 32            | 0.934   | 39            | 4             | 0.471   |
| No                     | 23        | 34         |          | 8             | 49            |          | 15            | 42            |         | 49            | 8             |         |
| Vital states           |           |            |         |               |               |         |               |               |         |               |               |         |
| Alive                  | 12        | 26         | .002*   | 1             | 37            | .024*   | 5             | 33            | .022*   | 31            | 7             | 0.122   |
| Dead                   | 39        | 23         |          | 11            | 51            |          | 21            | 41            |         | 57            | 5             |         |
| Tumor size             |           |            |         |               |               |         |               |               |         |               |               |         |
| <=5                    | 38        | 36         | 0.906   | 9             | 65            | 0.933   | 22            | 52            | 0.151   | 67            | 7             | 0.187   |
| >5                     | 13        | 13         |          | 3             | 23            |          | 4             | 22            |         | 21            | 5             |         |
| Tumor location         |           |            |         |               |               |         |               |               |         |               |               |         |
| Central type           | 35        | 29         | 0.325   | 7             | 57            | 0.663   | 17            | 47            | 0.864   | 58            | 6             | 0.281   |
| Peripheral type        | 16        | 20         |          | 5             | 31            |          | 9             | 27            |         | 30            | 6             |         |
| Tumor types            |           |            |         |               |               |         |               |               |         |               |               |         |
| SCC                    | 34        | 33         | 0.366   | 7             | 60            | 0.629   | 18            | 49            | 0.694   | 57            | 10            | 0.423   |
| Adenocarcinoma         | 15        | 16         |          | 5             | 26            |          | 8             | 23            |         | 29            | 2             |         |
| Small cell carcinoma   | 2         | 0          |          | 0             | 2             |          | 0             | 2             |         | 2             | 0             |         |
| Expression of GSDME    |           |            |         |               |               |         |               |               |         |               |               |         |
| Low expression         | –         | –          | –        | 10            | 41            | .017*   | 17            | 34            | .088    | 47            | 4             | 0.192   |
| High expression        | –         | –          | –        | 2             | 47            |         | 9             | 40            |         | 41            | 8             |         |
| Expression of caspase-3|           |            |         |               |               |         |               |               |         |               |               |         |
| Low expression         | 10        | 2          | .017*   | –             | –             | –        | 8             | 4             | .001*   | 11            | 1             | 0.677   |
| High expression        | 41        | 47         |          | –             | –             |          | 18            | 70            |         | 77            | 11            |         |
| Expression of caspase-8|           |            |         |               |               |         |               |               |         |               |               |         |
| Low expression         | 17        | 9          | .088    | 8             | 18            | .001*   | –             | –             | –        | 24            | 2             | 0.432   |
| High expression        | 34        | 40         |          | 4             | 70            |          | –             | –             |         | 64            | 10            |         |
| Expression of caspase-9|           |            |         |               |               |         |               |               |         |               |               |         |
| Low expression         | 47        | 41         | 0.192   | 11            | 77            | 0.677   | 24            | 64            | 0.432   | –             | –             |         |
| High expression        | 4         | 8          | 1        | 11            | 1             | 2        | 10            | –             |         | –             |               |         |

Note: *p < .05 was considered significant.
3 | RESULTS

3.1 | Expression levels of GSDME, caspase-3, caspase-8, and caspase-9 in lung cancer tissues and their association with clinicopathological parameters

Through the analysis of immunohistochemical staining of pathological sections of tissues from 100 patients with lung cancer, we found that the expression level of GSDME in lung cancer tissues was relatively higher than that in the adjacent normal tissues (Figure 1A). GSDME expression levels were found to be higher in the cell membranes of some lung cancer tissues, which is consistent with the possibility that GSDME causes cell disintegration and death by forming holes in the cell membrane.

Table 3 shows the relationship between GSDME expression and the clinical and pathological parameters of the patients. It was observed that patients with high GSDME expression experienced statistically fewer lymph node metastasis and had a significantly higher prognostic survival rate than patients with low GSDME expression. Therefore, GSDME may be an important factor affecting the postoperative survival of patients. In addition, there was a positive correlation between the expression level of GSDME and the stage of lymph node metastasis in patients with advanced tumors. This indicates that GSDME may have an inhibitory effect on tumor growth.

In this study, the expression of caspase-9 in lung cancer tissues was lower than expected (Figure 1D). As shown in Table 3, caspase-9 was weakly expressed in most of the cancer tissues, and the stratified expression levels of the different clinicopathological parameters were not significantly different (p > .05). On the other hand, caspase-3 and caspase-8 were highly expressed in lung cancer tissues, and they could be considered as possible prognostic factors (Figure 1B, C).

3.2 | Correlation analysis between GSDME, caspase-3, caspase-8, and caspase-9 levels

To understand whether the expression levels of GSDME, caspase-3, caspase-8, and caspase-9 correlated with each other and whether there were correlations with certain clinicopathological parameters, we calculated Spearman’s rank-order correlation coefficient. The statistical results are shown in Table 4. There was a significant correlation between high expression of GSDME and postoperative survival status, lymph node metastasis, and caspase-3 (p < .05). There was a

| TABLE 4 | Correlations between GSDME, caspase-3, caspase-8, and caspase-9 expression levels, and clinicopathological parameters |
|----------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Variables | GSDME Spearman correlation | p value | caspase-3 Spearman correlation | p value | caspase-8 Spearman correlation | p value | caspase-9 Spearman correlation | p value |
| Age       | 0.133 | 0.187 | -0.112 | 0.268 | 0.082 | 0.419 | -0.039 | 0.698 |
| gender    | 0.04  | 0.696 | 0.054 | 0.592 | 0.125 | 0.215 | -0.054 | 0.592 |
| TNM stage | -0.178 | 0.076 | 0.01  | 0.924 | -0.002 | 0.987 | -0.124 | 0.218 |
| Pathologic grade | -0.016 | 0.878 | -0.137 | 0.175 | -0.106 | 0.295 | 0.137 | 0.173 |
| Lymphatic invasion | -0.245 | 0.14* | 0.072 | 0.476 | 0.008 | 0.935 | -0.072 | 0.476 |
| Vital states | 0.304 | 0.002* | 0.226 | 0.024* | 0.229 | 0.22* | 0.155 | 0.124 |
| Tumor size | 0.012 | 0.907 | 0.008 | 0.934 | 0.143 | 0.154 | 0.132 | 0.191 |
| Tumor location | 0.098 | 0.33 | -0.044 | 0.667 | 0.017 | 0.866 | 0.108 | 0.286 |
| Tumor types | -0.062 | 0.538 | 0.093 | 0.36 | 0.014 | 0.886 | 0.099 | 0.327 |
| Expression of GSDME | - | - | 0.239 | 0.017* | 0.171 | 0.09 | 0.131 | 0.196 |
| Expression of caspase-3 | 0.239 | 0.017* | - | - | 0.342 | <.001* | 0.042 | 0.681 |
| Expression of caspase-8 | 0.171 | 0.09 | 0.342 | <.001* | - | - | 0.079 | 0.437 |
| Expression of caspase-9 | 0.131 | 0.196 | 0.042 | 0.681 | 0.079 | 0.437 | - | - |

Note: *p < .05 was considered significant.
correlation between the high expression levels of caspase-3 and caspase-8; there was also a significant correlation between the high expression levels of both caspase-3 and caspase-8 and the postoperative survival status \((p < .05)\). There was, unexpectedly, no correlation between the expression of caspase-9 and other variables; nor was there any correlation between the expression of caspase-9 and the survival rate of patients.

### 3.3 Relationships between the expression levels of GSDME, caspase-3, caspase-8, and caspase-9 and survival rate

Univariate and multivariate Cox proportional hazard models were used to examine the relationships between GSDME, caspase-3, caspase-8, and caspase-9 expression levels, related clinicopathological parameters, and patient survival rates. The corresponding risk ratios were also considered. The statistical results are shown in Tables 5 and 6. The Cox univariate analysis showed that GSDME expression, caspase-3 expression, TNM staging, lymph node metastasis, and tumor size were all meaningful variables that affected the survival time of patients after surgery.

We next conducted the Cox multivariate regression analysis on the above-mentioned significant influencing factors and their corresponding Cox univariate analyses. We found that not all the significant univariate variables showed significant differences in the multivariate analysis. However, the differences in the expression levels of GSDME remained significant. This confirms that GSDME is not only an influencing factor affecting the survival status, but also an independent prognostic factor of the patients with lung cancer. Thus, GSDME may be used for the clinical treatment and prognostic evaluation of patients with lung cancer. In addition, we plotted the survival curve of each variable and clinicopathological parameters by using the Kaplan Meier survival analysis, as shown in Figure 2.

### 4 | DISCUSSION

The incidence and mortality rates of lung cancer have always been high, with surgical resection as the predominant standard treatment. However, the postoperative survival rate of patients is not ideal. The reported 5-year survival rate for patients with lung cancer was 15.6% in 2011 and 19.4% in 2019.\(^1\) To achieve a lower mortality rate and a longer survival period, the exploration of lung cancer-related biomarkers has become a quintessential step in the treatment of lung cancer. In the present study, we explored the possible relationship between cell pyroptosis, the occurrence of lung cancer, and the prognosis of patients with this disease.

Pyroptosis is a form of programmed cell death characterized by cell membrane pore formation, cytoplasmic swelling, membrane rupture, and the release of cytoplasmic contents into the extracellular environment, which amplifies local or systemic inflammation.\(^11,12\) The pore-forming proteins of the GSDM family were shown to be involved in the activation of pyroptosis in 2001, and since then, they have been undergoing increased scientific scrutiny.\(^13,14\) GSDMD was the first protein confirmed to be involved in cell pyroptosis as a substrate of caspases 1, 4, 5, and 11 in humans.\(^15,16\)

In 2017, Shao et al.\(^6\) found that GSDME, another member of the gasdermin family, also participated in pyroptosis. However, GSDME was activated by caspase-3,\(^17\) which is an important factor in the process of apoptosis. It was therefore concluded that cells with high GSDME expression levels are activated by caspase-3 to redirect caspase-3-mediated apoptosis to pyroptosis.\(^7,13\)

GSDME and GSDMD share the same gasdermin N-terminal structure that gives them the ability to form pores.\(^7,10,18\) When GSDMD and GSDME are cleaved by caspses, their gasdermin N-terminal domains translocate and form oligomers in the plasma membrane, thereby leading to the formation of transmembrane pores and the release of cell inclusions.\(^16,19,20\) The cells then disintegrate and die, causing secondary inflammation.

It has been reported that the expression of GSDME in most cancer tissues is low or even absent.\(^8\) However, other reports described GSDMD and GSDME expression in a variety of cell types, including epithelial cells (HeLa), kidney cells (HEK293T), melanoma (A375), and lung cells (A549).\(^16,21,22\) Additionally, in breast cancer, the decrease in GSDME levels is associated with a decrease in the survival rate,\(^7,8\) indicating that GSDME may be a tumor suppressor. In primary gastric and colorectal cancers, GSDME is inhibited by methylation.\(^23,24\) GSDME has also been found to be methylated in estrogen receptor-positive breast cancer and associated with lymph node metastasis.\(^25\) In esophageal squamous cell carcinoma (ESCC) tissues, the expression level of GSDME has been reported to be higher than in normal esophageal tissues. Therefore, the level of GSDME in biopsy materials can be used as a prognostic indicator of ESCC.\(^10\)

In the present study, we used immunohistochemical staining to analyze the relationship between GSDME expression level and the prognosis of patients with lung cancer. Our results showed that high levels of GSDME expression in cancer tissues of patients with lung cancer was associated with a higher survival rate after surgery. In addition, patients in the high GSDME expression group had significantly fewer lymph node metatases. These results are consistent with the above-mentioned reports suggesting that GSDME may be a tumor suppressor.
In our current study, 110 patients with lung cancer had a high average GSDME expression rate of 49%. From the statistical analysis, we found that patients with high GSDME expression had a longer postoperative survival time and fewer lymph node metastases in advanced tumors. This indicates that low GSDME expression may lead to more aggressive carcinogenic phenotypes. As a tumor suppressor, GSDME may slow down tumor growth and invasion. This is consistent with the findings of a significant increase in cell death in tumors over-expressing GSDME reported by Wang et al.\textsuperscript{16} This may suggest that stimulation of pyroptosis in cancer tissues could be a new direction.

**FIGURE 2** Kaplan–Meier curves of the overall survival of lung cancer patients. The overall survival rates were grouped according to the expression levels of gasdermin E (GSDME) (A), caspase-3 (B), caspase-8 (C), caspase-9 (D), the presence or absence of lymph node metastasis (E), TNM stage (F), tumor composition (G), tumor size (H), tumor location (I), pathological grade of tumor tissue (J), gender (K), and age (L). M. Cox multivariate analysis. The overall survival time of the groups with high expression of GSDME and caspase-3 (A, B) was significantly higher than that of the groups with low expression levels of these proteins ($p < .05$). The overall survival time of patients without lymph node metastasis and with tumor diameters of $\leq$ 5 cm (E, H) was significantly higher than that of patients with lymph node metastasis and tumor diameter $> 5$ cm ($p < .05$). TNM stage was also an important factor affecting overall survival (F, $p < .01$).
for cancer treatment. However, the mechanisms behind the inhibition of tumor cell growth by pyroptosis without concomitant destruction of normal body tissues remain to be further studied.

Caspases are a type of cysteine proteases that cleave sites located after aspartic acid residues at specific recognition sites. The activation of these caspases is a biochemical marker of apoptosis.26 Apoptosis has been defined as a type of programmed cell death,27 which proceeds through two classical signal transduction pathways: the external and internal pathways.28 The external pathway is mediated by caspase-8, whereas the internal pathway is triggered by caspase-9. Both pathways trigger apoptosis by cleaving the downstream executive protein caspase-3.29

The caspase family is divided into two categories according to the functions of their members in apoptosis (caspase-3/6/7/8/9) and inflammation (caspase-1/4/5/12). Caspase-8 and caspase-9 are promoters of caspases in the cascade of apoptotic signals; caspase-3, which is cleaved and activated by caspase-8 and caspase-9, is the main executor of caspases.30 Caspase-3 is involved in the regulation of pyrolysis through its function of cleaving GSDME. This means that when GSDME is overexpressed, caspase-3-mediated apoptosis is redirected into pyroptosis.7,13

However, in this study, we found that only the expression levels of GSDME, caspase-8, and caspase-3 were significantly correlated, whereas the expression of caspase-9 was low in most cancer tissues. We also found that there was no correlation between the expression levels of caspase-3 and caspase-8. This was surprising because it is known that caspase-9 is an upstream mediator of caspase-3 activation during the mitochondria-dependent apoptosis.31 This phenomenon indicates that there may be a predominance issue between the actions of caspase-8 and caspase-9 upstream of caspase-3 in some tissues.

In this study, caspase-8 played a major role with its function upstream of caspase-3. Furthermore, the high expression levels of caspase-3 correlated with the high expression level of caspase-8. Interestingly, caspase-9 is also reported to be a substrate for caspase-3 during apoptosis.31 However, due to the limitation of conditions, the specific internal mechanisms of the actions of caspase-8 and caspase-9 upstream of caspase-3 have not been explored in this study.

5 | CONCLUSIONS

Our study found that the expression level of GSDME in lung cancer tissues was higher than in the normal tissues adjacent to cancer tissues. Furthermore, we found that tissues from lung cancer patients with higher GSDME expression had fewer lymph node metastases. Based on the univariate and multivariate analyses, we found that the highest expression level of GSDME in lung cancer tissues was associated with longer postoperative survival time, indicating that GSDME may be an independent factor affecting the prognosis of patients with lung cancer. Furthermore, the expression level of GSDME correlated with the expression level of caspase-3. This study also confirmed that caspase-8 acts as a promoter, acting upstream of caspase-3. Based on the univariate analysis, we also found that caspase-3 is an important factor affecting the postoperative survival time of patients. However, further research is required to elucidate the exact role of GSDME and its related proteins in cancer.

ACKNOWLEDGMENTS

I would like to thank all the authors for their efforts.

CONFLICT OF INTEREST

We declare that there are no conflicts of interest on the parts of any of the authors.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

AUTHOR CONTRIBUTIONS

YLH: Data curation (equal); formal analysis (equal); methodology (equal); writing – original draft (lead); writing – review and editing (lead). GHZ: Data curation (equal); formal analysis (equal); project administration (equal). QZ: Data curation (equal); methodology (equal). XW: Data curation (equal); formal analysis (equal); methodology (equal). LGW: Formal analysis (equal); project administration (lead); supervision (equal); writing – review and editing (supporting).

ORCID

Yuan-Li Huang https://orcid.org/0000-0001-9899-811X

REFERENCES

1. Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1-24.
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
3. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1-19.
4. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
5. Jiang M, Qi L, Li L, et al. The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer. Cell Death Discov. 2020;6:112.
6. Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 2017;42(4):245-254.
7. Wang Y, Gao W, Shi X, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99-103.
8. Zhang Z, Zhang Y, Xia S, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579(7799):415-420.
9. Xia X, Wang X, Cheng Z, et al. The role of pyroptosis in cancer: pro-cancer or pro-“host”? Cell Death Dis. 2019;10(9):650.
10. Wu M, Wang Y, Yang D, et al. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma. EBioMedicine. 2019;41:244-255.
11. Fink SL, Cookson BT. Pyroptosis and host cell death responses during salmonella infection. Cell Microbiol. 2007;9(11):2562-2570.
12. Fink SL, Bergsbaken T, Cookson BT. Anthrax lethal toxin and salmonella elicit the common cell death pathway of caspase-1-dependent
pyroptosis via distinct mechanisms. *Proc Natl Acad Sci U S A*. 2008;105(11):4312-4317.

13. Wang YY, Liu XL, Zhao R. Induction of pyroptosis and its implications in cancer management. *Front Oncol*. 2019;9:971.

14. Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. *Trends Microbiol*. 2001;9(3):113-114.

15. Kayagaki N, Stowe IB, Lee BL, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature*. 2015;526(7575):666-671.

16. Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature*. 2015;526(7575):660-665.

17. Rogers C, Fernandes-Alnemri T, Mayes L, et al. Cleavage of DFNAS by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. *Nat Commun*. 2017;8:14128.

18. He WT, Wan H, Hu L, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion. *Cell Res*. 2015;25(12):1285-1298.

19. Ding J, Wang K, Liu W, et al. Pore-forming activity and structural autoinhibition of the gasdermin family. *Nature*. 2016;535(7610):111-116.

20. Rogers C, Erkes DA, Nardone A, et al. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. *Nat Commun*. 2019;10(1):1689.

21. Zhang CC, Li CG, Wang YF, et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation. *Apoptosis*. 2019;24(3-4):312-325.

22. Zhou B, Zhang JY, Liu XS, et al. Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis. *Cell Res*. 2018;28(12):1171-1185.

23. Kim MS, Chang X, Yamashita K, et al. Aberrant promoter methylation and tumor suppressive activity of the DFNAS gene in colorectal carcinoma. *Oncogene*. 2008;27(25):3624-3634.

24. Akino K, Toyota M, Suzuki H, et al. Identification of DFNAS as a target of epigenetic inactivation in gastric cancer. *Cancer Sci*. 2007;98(1):88-95.

25. Kim MS, Lebron C, Nagpal JK, et al. Methylation of the DFNAS increases risk of lymph node metastasis in human breast cancer. *Biochem Biophys Res Commun*. 2008;370(1):38-43.

26. Wang Y, Zhao X, Wang L, et al. Caspase-3 mediated feedback activation of apical caspases in doxorubicin and TNF-alpha induced apoptosis. *Apoptosis*. 2006;11(1):197-1997.

27. Ijiri Y, Kato R, Sadamatsu M, et al. Contributions of caspase-8 and -9 to liver injury from CYP2E1-produced metabolites of halogenated hydrocarbons. *Xenobiotica*. 2018;48(1):60-72.

28. Pileczki V, Cojocneanu-Petric R, Maralani M, et al. MicroRNAs as regulators of apoptosis mechanisms in cancer. *Clujul Med*. 2016;89(1):50-55.

29. Wu MH, Jin XK, Yu AQ, et al. Caspase-mediated apoptosis in crustaceans: cloning and functional characterization of EsCaspase-3-like protein from Eriocheir. *Fish Shellfish Immunol*. 2014;41(2):625-632.

30. Liu PF, Hu YC, Kang BH, et al. Expression levels of cleaved caspase-3 and caspase-3 in tumorigenesis and prognosis of oral tongue squamous cell carcinoma. *PloS One*. 2017;12(7):e0180620.

31. Wu Y, Wang D, Wang X, et al. Caspase 3 is activated through caspase 9 instead of caspase 8 during H2O2-induced apoptosis in HeLa cells. *Cell Physiol Biochem*. 2011;27(5):539-546.